Expression of miR-664-3p in Osteosarcoma and Its Effects on the Proliferation and Apoptosis of Osteosarcoma Cells
Background: To explore the expression level of miR-664-3p in osteosarcoma and its effects on the proliferation and apoptosis of osteosarcoma cells.
Methods: Specimens of osteosarcoma tissues were collected from 41 cases undergoing surgical treatment in the Orthopedics Department of Wuhan Puai Hospital, Wuhan, China from January 2015 to February 2018. Another 40 cases of normal bone tissue were collected. The expression of miR-664-3p were detected using quantificational real-time polymerase chain reaction. miR-664-3p mimics, miR-664-3p inhibitor and miR-664-3p negative control (NC) were used to transfect U2-OS, which were named as mimics group, inhibitor group and NC group, respectively. MTT assay was adopted to detect the effects of microRNA-664-3p on the proliferation of U2-OS after 24, 48, 72, 96 and 120 hours of transfection. Flow cytometry was applied to measure the apoptosis rate of U2-OS after miR-664-3p transfection. Finally, Western Blot was employed to detect the expression of proteolipid protein 2 (PLP2).
Results: The total apoptosis rate of cells in the inhibitor group was obviously higher than those in the mimics group and the NC group (P<0.001). The relative expression level of PLP2 in the inhibitor group was significantly lower than those in the mimics group and the NC group (P<0.001).
Conclusion: MiR-664-3p may be involved in the occurrence and development of osteosarcoma, and can regulate the proliferation and apoptosis of U2-OS cells, and the expression of PLP2. Besides, miR-664-3p may become a novel molecular biological indicator for the diagnosis, targeted treatment and prognosis assessment of osteosarcoma.
2. Wang S, Ren T, Huang Y et al (2017). BMPR2 and HIF1-alpha overexpression in resected osteosarcoma correlates with distant metastasis and patient survival. Chin J Cancer Res, 29: 447-454.
3. Angelini A, Ceci F (2017). The role of (18)F-FDG PET/CT in the detection of osteo-sarcoma recurrence. Eur J Nucl Med Mol Imaging, 44: 1712-1720.
4. He X, Gao Z, Xu H, Zhang Z, Fu P (2017). A meta-analysis of randomized control trials of surgical methods with osteosar-coma outcomes. J Orthop Surg Res, 12: 5.
5. Guenther LM, Rowe RG, Acharya PT et al (2018). Response Evaluation Criteria in Solid Tumors (RECIST) following neo-adjuvant chemotherapy in osteosarcoma. Pediatr Blood Cancer, 65(4).
6. Duan Z, Gao Y, Shen J et al (2017). miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo. Mol Oncol, 11: 151-166.
7. Kulda V, Svaton M, Mukensnabl P et al (2018). Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy. Oncol Lett, 15: 592-599.
8. Rupaimoole R, Slack FJ (2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseas-es. Nat Rev Drug Discov, 16: 203-222.
9. Peng L, Chen Y, Ma N, Chen X (2017). NARRMDA: negative-aware and rating-based recommendation algorithm for miRNA-disease association prediction. Mol Biosyst, 13: 2650-2659.
10. Wang Y, Wang N, Zeng X et al (2017). Mi-croRNA-335 and its target Rock1 syner-gistically influence tumor progression and prognosis in osteosarcoma. Oncol Lett, 13: 3057-3065.
11. Lee BP, Buric I, George-Pandeth A et al (2017). MicroRNAs miR-203-3p, miR-664-3p and miR-708-5p are associated with median strain lifespan in mice. Sci Rep, 7: 44620.
12. Vasquez L, Tarrillo F, Oscanoa M et al (2016). Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Ex-tremities in Children: A 15-Year Single-Institution Experience. Front Oncol, 6: 22.
13. Cheng J, Chen Y, Zhao P et al (2017). Dysregulation of miR-638 in hepatocellu-lar carcinoma and its clinical significance. Oncol Lett, 13: 3859-3865.
14. Chen D, Liu D, Chen Z (2017). Potential therapeutic implications of miRNAs in osteosarcoma chemotherapy. Tumour Biol, 39: 1010428317705762.
15. Ferrari S, Bielack SS, Smeland S et al (2018). EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori, 104: 30-36.
16. Jiang L, He A, He X, Tao C (2015). Mi-croRNA-126 enhances the sensitivity of osteosarcoma cells to cisplatin and meth-otrexate. Oncol Lett, 10: 3769-3778.
17. Xu JF, Wang YP, Zhang SJ et al (2017). Ex-osomes containing differential expression of microRNA and mRNA in osteosar-coma that can predict response to chem-otherapy. Oncotarget, 8: 75968-75978.
18. Yang X, Liu F, Zhang Y, Wang L, Cheng Y-f (2017). Cold-responsive miRNAs and their target genes in the wild eggplant species Solanum aculeatissimum. BMC Genomics, 18: 1000.
19. Farina FM, Inguscio A, Kunderfranco P et al (2017). MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apop-tosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines. Cell Death Dis, 8: e2890.
20. Koetz-Ploch L, Hanniford D, Dolgalev I et al (2017). MicroRNA-125a promotes re-sistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res, 30: 328-338.
21. Zhang Q, Xiao X, Li M et al (2013). Acar-bose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats. PLoS One, 8: e79697.
22. Zhu H, Miao MH, Ji XQ, Xue J, Shao XJ (2015). miR-664 negatively regulates PLP2 and promotes cell proliferation and inva-sion in T-cell acute lymphoblastic leu-kaemia. Biochem Biophys Res Commun, 459: 340-345.
23. Zou Y, Chen Y, Yao S et al (2018). MiR-422a weakened breast cancer stem cells properties by targeting PLP2. Cancer Biol Ther, 19: 436-444.
24. Ozawa H, Sonoda Y, Suzuki T et al (2012). Knockdown of proteolipid protein 2 or focal adhesion kinase with an artificial microRNA reduces growth and metasta-sis of B16BL6 melanoma cells. Oncol Lett, 3: 19-24.
25. Iannone R, Miele L, Maiolino P, Pinto A, Morello S (2014). Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res, 4: 172-181.
26. Ding Z, Jian S, Peng X et al (2015). Loss of MiR-664 Expression Enhances Cutane-ous Malignant Melanoma Proliferation by Upregulating PLP2. Medicine (Baltimore), 94: e1327.